0001209191-19-018958.txt : 20190312
0001209191-19-018958.hdr.sgml : 20190312
20190312181327
ACCESSION NUMBER: 0001209191-19-018958
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190308
FILED AS OF DATE: 20190312
DATE AS OF CHANGE: 20190312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heartlein Michael
CENTRAL INDEX KEY: 0001744680
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38550
FILM NUMBER: 19676342
MAIL ADDRESS:
STREET 1: C/O TRANSLATE BIO, INC.
STREET 2: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Translate Bio, Inc.
CENTRAL INDEX KEY: 0001693415
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 611807780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-945-7361
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: RaNA Therapeutics, Inc.
DATE OF NAME CHANGE: 20161228
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-08
0
0001693415
Translate Bio, Inc.
TBIO
0001744680
Heartlein Michael
C/O TRANSLATE BIO, INC.
29 HARTWELL AVE
LEXINGTON
MA
02421
0
1
0
1
Chief Scientific Officer
Chief Technical Officer
Stock Option (right to buy)
7.95
2019-03-08
4
A
0
150000
0.00
A
2029-03-07
Common Stock
150000
150000
D
This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
/s/ Paul D. Burgess, as attorney-in-fact
2019-03-12